SCHEMBL24287482

SCHEMBL24287482

Cc1ccccc1Oc1cc(Cl)nc(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NPC1 O15118 1/20 0.48
TSHR P16473 1/20 0.48
RAB9A P51151 1/20 0.48
HPGD P15428 2/20 0.47
ALDH1A1 P00352 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
ACHE P22303 4/20 0.44
BCHE P06276 3/20 0.44
GCK P35557 1/20 0.39
AKT1 P31749 1/20 0.38
PIK3CA P42336 1/20 0.38
MTOR P42345 1/20 0.38
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7303768 0.81 SMN1; SMN2 (0.48) ARSMN1; SMN2MEN1KMT2ANPC1
SCHEMBL10879583 0.81 ALDH1A1 (0.46) ARSMN1; SMN2KMT2AHPGDALDH1A1
SCHEMBL10882722 0.78 ALDH1A1 (0.44) MEN1KMT2AALDH1A1GCKSLC6A2
SCHEMBL24287429 0.78 S1PR2 (0.35) SMN1; SMN2MEN1KMT2AALDH1A1CYP1A2
SCHEMBL10883303 0.78 LMNA (0.41) SMN1; SMN2MEN1KMT2ANPC1TSHR
SCHEMBL24287427 0.77 AR (0.44) ARSMN1; SMN2HPGDACHEBCHE
SCHEMBL10881078 0.77 MAPT (0.44) ARSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL5340839 0.76 NPSR1 (0.59) ARSMN1; SMN2MEN1KMT2ANPC1
SCHEMBL7690257 0.75 ALDH1A1 (0.59) ARSMN1; SMN2MEN1KMT2ANPC1
SCHEMBL12653055 0.75 HTR2A (0.54) ARSMN1; SMN2MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022076629-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 WO disclosed